Interestingly, our preclinical data demonstrated that metformin represents anti-tumor/anti-metastatic effect only when prescribed with a DPP-4 inhibitor; nevertheless, metformin alone had no impact on basal breast cancer proliferation and metastasis in vivo [38]. The gene discussed is DPP4; the disease is breast cancer.